Myeloid-derived suppressor cells in autoimmunity, inflammation and cancer

Thursday, November 07, 2013 — Concurrent Symposia Session II
10:00 a.m. – 12:00 p.m.	FAES Academic Center lower-level Classrooms 6 and 7

Chair

Tim Greten, NCI

Program

Tumor associated myeloid derived suppressor cells (MDSC) include populations of immature myeloid cells and myeloid progenitors present in mice and humans with cancer. While murine MDSC are characterized by the dual expression of Gr-1 and CD11b, phenotypic markers for human MDSC are less well characterized. MDSC produce high levels of arginase, nitric oxide, reactive oxygen species (ROS), prostaglandin E2 and cytokines and are characterized functionally by their ability to suppress T cell activity and proliferation. Murine MDSCs have been categorized into two distinct subsets: CD11b+Ly6ChiLy6Gneg monocytic and CD11b+Ly6CloLy6G+ polymorphonuclear. There is considerable interest in the NIH community in understanding the biology of MDSC, defining their contribution to carcinogenesis and inflammation, and establishing the value of targeting MDSC in an effort to optimize tumor immunotherapy.

Hepatic MDSC and their role in cancer and inflammation
Tim Greten, NCI

MDSC blindness: The tBreg-Treg axis in regulation of cancer metastasis
Arya Biragyn, NIA

Commensal bacteria control cancer response to therapy by modulating myeloid cell function in the tumor microenvironment
Romina Goldszmid, NCI

TGF-beta regulates MDSC function
Li Yang, NCI

Modulation of MDSC function by TLR activation
Dennis Klinman, NCI

Blockade of CD47 induces radiation tumor growth delay through regulation of autophagy and bioenergetics of the tumor microenvironment; FARE Award Winner
David Soto Pantoja, NCI